Align Technology (ALGN)
(Delayed Data from NSDQ)
$212.15 USD
+1.37 (0.65%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $211.69 -0.46 (-0.22%) 5:08 PM ET
4-Sell of 5 4
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$212.15 USD
+1.37 (0.65%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $211.69 -0.46 (-0.22%) 5:08 PM ET
4-Sell of 5 4
C Value B Growth C Momentum C VGM
Zacks News
Align Technology (ALGN) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of -5.31% and 3.46%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Align Technology (ALGN) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) third-quarter 2023 results are likely to reflect strength in the Clear Aligner business.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) on robust volume growth in the Plasma business and upbeat guidance.
Analysts Estimate West Pharmaceutical Services (WST) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align (ALGN) Gains From New Launches, Strategic Partnerships
by Zacks Equity Research
Align Technology (ALGN) has well-established relationships with many DSOs, especially in the United States.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the latest acquisition.
Align Technology (ALGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add Cencora (COR) to Your Portfolio Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
STERIS' (STE) Improved Volume, New Buyouts Drive Growth
by Zacks Equity Research
On the capital equipment side for STERIS (STE), the easing of supply-chain issues and reduced lead times are boosting shipments.
PetMeds (PETS) to Advance Pet Care With New Collaboration
by Zacks Equity Research
PetMeds (PETS) is positioning itself more firmly in the field of pet health and wellness as a result of its established reputation in the pet pharmaceutical industry.
Orthofix (OFIX) Secures FDA 510k Clearance for OsteoCove Graft
by Zacks Equity Research
Orthofix (OFIX) announces the full commercial availability of the OsteoCove synthetic graft after gaining the FDA's nod.
Here's Why You Should Buy Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors remain optimistic about Edward Lifesciences (EW) on the strength of the Critical Care business and TAVR sales.
Here's Why You Should Invest in Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors are optimistic about Insulet (PODD) on continued expansion in Omnipod's market access.
Alcon (ALC) Stock Up 9.7% YTD: Will the Rally Continue?
by Zacks Equity Research
Alcon (ALC) continues gaining from the company's diverse portfolio, incremental innovation, and new product launches.
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Align Technology (ALGN) and Artivion (AORT) have performed compared to their sector so far this year.
Boston Scientific's (BSX) Wavewriter Alpha SCS Gets FDA's Nod
by Zacks Equity Research
Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) due to its impressive acquisition deals and end-market strength.
Here's Why You Should Retain Fresenius Medical (FMS) for Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Masimo (MASI) Gets De Novo for Novel Oxygen Status Index ORi
by Zacks Equity Research
Masimo's (MASI) ORi parameter gets De Novo from the FDA, providing option for continuous monitoring of oxygen level in surgical patients leading to better management of hyperoxia.
Teleflex (TFX) Advances Urology Portfolio With New Buyout
by Zacks Equity Research
Teleflex's (TFX) recent buyout is in line with its strategy of acquiring assets that accelerate the rate of expansion.
Globus Medical (GMED) Gains From NuVasive Buyout, Innovation
by Zacks Equity Research
Globus Medical (GMED) is particularly seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Labcorp (LH) Launches Biomarker Test for Alzheimer's Disease
by Zacks Equity Research
Labcorp's (LH) new test, ATN Profile, is likely to accelerate the path to the diagnosis of Alzheimer's disease.
5 Large-Cap Stocks to Buy on the Dip for Q4 2023
by Nalak Das
We have narrowed our search to five large-cap (market capital > $10 billion) stocks with attractive valuations. These stocks are: TWLO, KDP, ULTA, ALGN, ZBH.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Fresenius Medical (FMS) Sinks on Potential Rise in Competition
by Zacks Equity Research
Fresenius Medical's (FMS) shares decline more than 17% on Wednesday following news of the successful clinical trial of a competing drug in preventing kidney disease.